Skip to main content
Have a personal or library account? Click to login
The Influence of Antipsychotics on the Quality of Life of Patients with Schizophrenia in a Long-stay Psychiatric Facility Cover

The Influence of Antipsychotics on the Quality of Life of Patients with Schizophrenia in a Long-stay Psychiatric Facility

EABR. Experimental and Applied Biomedical Research
Volume 15 (2014): Issue 2 (June 2014)
By:  and    
Open Access
|Jun 2014
References

References

  1. 1. Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ.Hospital and community-based care for patients with chronic schizophrenia in Hong Kong- quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 2003; 38(4): 196-203.
    Open DOISearch in Google Scholar
  2. 2. Salome F, Petitjean F, Germain C, Demant JC. The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients’ expectations.
    Search in Google Scholar
  3. A comparative study. Encephale 2004; 30(1): 60-8.
    Open DOISearch in Google Scholar
  4. 3. Rossler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C.Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand. 1999; 100(2): 142-8.
    Open DOISearch in Google Scholar
  5. 4. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010; 26(4): 787-801.
    Open DOISearch in Google Scholar
  6. 5. Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2): 109-19.
    Open DOISearch in Google Scholar
  7. 6. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia.Acta Psychiatr Scand Suppl. 2009; 438: 22-8.
    Open DOISearch in Google Scholar
  8. 7. www.who.int
    Search in Google Scholar
  9. 8. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L. The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. Qual Life Res. 2011; 20(7): 1079-89.
    Open DOISearch in Google Scholar
  10. 9. World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Genova: WHO, 1993.
    Search in Google Scholar
  11. 10. Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med. 2009; 87(9): 593-8.
    Search in Google Scholar
  12. 11. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71(1): 137-44.
    Open DOISearch in Google Scholar
  13. 12. Midori Fujikawa, Takashi Togo, Asuka Yoshimi et al Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro Psychopharmacology & Biological Psychiatry 2008; 32: 755-760.
    Open DOISearch in Google Scholar
  14. 13. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719-23.
    Open DOISearch in Google Scholar
  15. 14. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A,Wagner T, et al Prediction of remission as a combination of symptomatic and functionalremission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-7.
    Open DOISearch in Google Scholar
  16. 15. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry 2002; 159: 103-8.
    Open DOISearch in Google Scholar
  17. 16. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S et al The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psichiatry 2003; 18(5): 432-40.
    Open DOISearch in Google Scholar
  18. 17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt- LASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
    Open DOISearch in Google Scholar
  19. 18. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-12.
    Open DOISearch in Google Scholar
  20. 19. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW.Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-60.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/sjecr-2014-0012 | Journal eISSN: 2956-2090 (formerly 2335-075X, 2956-0454) | Journal ISSN: 2956-0454 (formerly 1820-8665)
Journal RSS Feed
Language: English, Croatian
Page range: 89 - 94
Submitted on: Jan 2, 2014
Accepted on: May 4, 2014
Published on: Jun 21, 2014
Published by: University of Kragujevac, Faculty of Medical Sciences
In partnership with: Paradigm Publishing Services
Keywords:
Quality of life,
chronic schizophrenia,
quality of life domains,
questionnaires
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2014 Aleksandra Petrovic Kitic, Slobodan Jankovic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 15 (2014): Issue 2 (June 2014)
Previous article
Next article